RBS Australia 19/03/2010 1 Buy $37.50 4.7%
The broker continues to be impressed by the continued strong demand growth for IVIG in Europe and it sees CSL as a key beneficiary given it continues to develop new uses such as a treatment for Alzheimer's.
With no major changes to its forecasts following its latest review the broker retains its Buy rating and $37.50 price target.
credit suisse - $40.50, page-31
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$302.20 |
Change
-3.830(1.25%) |
Mkt cap ! $146.0B | |||
| Open | High | Low | Value | Volume |
| $302.89 | $302.89 | $299.73 | $79.51M | 263.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 276 | $302.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $302.20 | 5 | 1 |
View Market Depth
| Last trade - 15.22pm 04/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |